Reviews/Novel Antibiotics/CAZ-AVI achieves clinical cure in most serious CRE infections
Caz Avi · NOVEL-AB-CAZAVI-03 · v2
The corpus contains only one study that directly measures whether ceftazidime-avibactam cures serious carbapenem-resistant infections, and that study [8] looked at a specific group: organ-transplant patients with bloodstream infections caused by one resistance type of Klebsiella. In that group most patients recovered, with clinical success around 80.7% to 83.1%, which is better than the comparison treatment. Two large high-quality trials [1][2] also show the drug works well, but they were run in abdominal and urinary infections caused by different, non-carbapenem-resistant bacteria, so they speak to the claim only indirectly. The corpus also records that the drug does not work against a second major resistance type (metallo-beta-lactamase producers) [7][9], which the claim's broad wording would sweep in. So the direction of the evidence favours the claim for one resistance type, but the direct support is a single observational study in a narrow population rather than a trial in carbapenem-resistant infection.
One retrospective observational cohort [8] of solid organ transplant recipients with carbapenemase-producing K. pneumoniae bloodstream infection reports CAZ-AVI clinical success of 80.7% at 14 days and 83.1% at 30 days (versus 60.6% on best available therapy), with adjusted odds ratios of 2.65 (95% CI 1.03-6.84) and 3.14 (95% CI 1.17-8.40). The pivotal RCTs show high cure rates in serious Gram-negative infection — 81.6% clinical cure in complicated intra-abdominal infection and 83.0% in its ceftazidime-resistant subgroup [1], and noninferiority in complicated urinary tract infection [2] — but in ceftazidime-resistant or nonsusceptible, non-CRE populations. Reviews in the corpus record that CAZ-AVI is active against KPC- and OXA-48-producing Enterobacteriaceae but not against metallo-beta-lactamase producers [7][9]. No corpus study measures clinical cure against metallo-beta-lactamase-producing CRE. The contested point: The division is whether one observational cohort [8] in KPC-producing K. pneumoniae bloodstream infection among transplant recipients can carry a general statement about 'most serious CRE infections.' The direct cure data clear the 'most' threshold for that one serine-carbapenemase population, but the corpus provides no clinical-cure data for the metallo-beta-lactamase CRE the broad claim also covers [7][9].
All 18 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Novel Antibiotics, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The CRE-specific evidence rests entirely on one retrospective observational cohort [8] confined to solid organ transplant recipients with KPC-producing K. pneumoniae bloodstream infection (66 on CAZ-AVI); this narrow population cannot support 'most serious CRE infections' as a general statement, and observational design admits confounding by indication despite propensity adjustment.
Indirectness: the two RCTs [1][2] test ceftazidime-resistant/nonsusceptible pathogens in cIAI and cUTI, which is not equivalent to carbapenem-resistant Enterobacteriaceae; they do not evaluate the CRE population the claim names and cannot carry it.
Where it remains uncertain. The only direct CRE outcome data are confined to KPC infection in a narrow transplant population [8], while the drug is not active against metallo-beta-lactamase-producing strains [7][9], which 'most serious CRE' would include.
Aleatory
The direct CRE cure estimate rests on 66 CAZ-AVI patients within 149 actively treated of 210 in [8], so success rates carry wide sampling variability.
Epistemic
No corpus RCT measures clinical cure in carbapenem-resistant Enterobacteriaceae; the CRE evidence is one non-randomised comparison against best available therapy [8].
Inferential
Extending a KPC (serine-carbapenemase) result [8] to 'most serious CRE' assumes the class behaves uniformly, which [7][9] contradict for MBL strains.
The load-bearing papers from a corpus of 18, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Indirect support: high CAZ-AVI cure rate against ceftazidime-resistant pathogens in cIAI, though not a carbapenem-resistant population.
“The clinical cure rate with ceftazidime-avibactam plus metronidazole for ceftazidime-resistant infections was comparable to that with meropenem (mMITT population, 83.0% and 85.9%, respectively)”
Panel auditInternal validity: high · scope of inference: Adults with complicated intra-abdominal infection, predominantly ceftazidime-susceptible and ceftazidime-resistant pathogens, not CRE.Key limitations: not a CRE population · cIAI only · noninferiority design
Indirect support: CAZ-AVI efficacy in serious Gram-negative cUTI, but ceftazidime-nonsusceptible is not CRE.
“combined symptomatic resolution/microbiological eradication at test of cure (TOC): 280 of 393 (71.2%) vs 269 of 417 (64.5%) patients (difference, 6.7% [95% CI, .30% to 13.12%])”
Panel auditInternal validity: high · scope of inference: Hospitalized adults with complicated UTI including acute pyelonephritis, mostly ceftazidime-susceptible pathogens.Key limitations: not a CRE population · cUTI only · ceftazidime-nonsusceptible is not CRE
Direct evidence that CAZ-AVI achieves clinical success in most (>80%) serious CRE (carbapenemase-producing K. pneumoniae bloodstream) infections.
“In conclusion, CAZ-AVI may be considered a first-line treatment in SOT recipients with CPKP-BSI.”
Panel auditInternal validity: medium · scope of inference: Solid organ transplant recipients with carbapenemase-producing K. pneumoniae bloodstream infection.Key limitations: retrospective · transplant-only population · observational confounding
3 of 18 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The claim is plausibly true for serine-carbapenemase CRE but the direct evidence is one observational cohort in a narrow population, so the corpus supports an Uncertain tier rather than a confident one.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No RCT of clinical cure in CRE. The only direct CRE outcome evidence is observational [8], which admits confounding by indication despite propensity adjustment. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised controlled trial of CAZ-AVI versus comparator for clinical cure in serious CRE infection.
Open question: Does CAZ-AVI achieve clinical cure in CRE infection when tested in a randomised controlled trial rather than an observational cohort? Why it is still open: The only CRE outcome evidence in the corpus is retrospective and observational [8]; no RCT addresses clinical cure in CRE.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19